NCT07028385View on ClinicalTrials.gov

Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions
HIV
Interventions
DRUG

Bariticinib 2 mg

Commercially available tablets containing 2 mg of barticiinib will be used. The tablets will be re-capsulated to keep the study blind.

OTHER

Placebo

Maltodextrin capsules with identical weight and appearance (shape, size, colour and flavour) as the bariticinib-containing capsules.

Trial Locations (1)

08916

Fundació Lluita contra les Infeccions - Hospital Universitari Germans Trias i Pujol, Badalona

All Listed Sponsors
collaborator

IrsiCaixa

OTHER

collaborator

University of Turin, Italy

OTHER

collaborator

Instituto de Salud Carlos III

OTHER_GOV

collaborator

Germans Trias i Pujol Hospital

OTHER

lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER